Do not rely upon any of the information provided on this site for medical diagnosis or treatment. Please consult your primary health care provider about any personal health concerns. This website does not provide any medical diagnosis, symptom assessment, health counseling or medical opinion for individual users. The information contained on this site is intended for information purposes only and does not constitute medical advice for patients. For more detailed information on prescription drugs, please consult a qualified healthcare professional.
NAMI has recently started endorsing the Partnership
for Prescription Assistance , a new program that seeks to boost
enrollment in existing Patient Assistance Programs by helping consumers
identify and apply for programs for which they may be eligible. This
may be a good place to start if you are unfamiliar with Assistance
Programs that might work for you - however, we don't yet know how
successful the Partnership is at enrolling people in good programs,
or how much they may charge for their service. If anyone has experiences
to share about the Partnership for Prescription Assistance (good or
bad), please email the administration at: [email protected]
Visit their website ( http:// ) or call 1-888-477-2669 if you are interested.
Free information sites about PAPs - include databases searchable by state, medication, or company name
In the traditional tests for antipsychotic effect, eg antagonism of stereotypic behaviour induced by dopamine agonists, the chemical groups of antipsychotics mentioned reveal equal but dosage-dependent activity. However, the antistereotypic effects of phenothiazines, butyrophenones, diphenylbutylpiperidines, and benzamides is strongly counteracted by the anticholinergic drug scopolamine, while the antistereotypic effect of thioxanthenes, eg flupentixol is not, or only very slightly, influenced by concomitant treatment with anticholinergics.